Hisazumi H, Uchibayashi T, Naito K, Misaki T, Miyazaki K
J Urol. 1975 Sep;114(3):394-8. doi: 10.1016/s0022-5347(17)67038-1.
The prevention of recurrences of bladder cancer was attemped in 48 patients by means of the combined intravesical instillation of thio-tepa and urokinase and in 28 patients through the instillation of thio-tepa alone. The recurrence rates of both therapies for the postoperative 18 months were 7.9 and 32.6 per cent, respectively, indicating a significant drop in the recurrence rate in the group subjected to the combined therapy. No significant difference was found between the 2 instillation groups in terms of the blood transmission of 32-P thio-tepa. Serious leukopenia was found in 2 of the 48 patients receiving the combined instillation therapy but we concluded that this was not attributable to the use of urokinase.
对48例患者尝试通过硫替派和尿激酶联合膀胱内灌注预防膀胱癌复发，对28例患者仅通过硫替派灌注预防膀胱癌复发。两种治疗方法术后18个月的复发率分别为7.9%和32.6%，表明联合治疗组的复发率显著下降。两个灌注组在32-P硫替派的血液转移方面未发现显著差异。在接受联合灌注治疗的48例患者中有2例出现严重白细胞减少，但我们得出结论，这并非归因于尿激酶的使用。
